Actionable molecular biomarkers in primary brain tumors

Tools

Item Type:	Review
Title:	Actionable molecular biomarkers in primary brain tumors
Creators Name:	Staedtke, V., a Dzaye, O.D. and Holdhoff, M.
Abstract:	Recent genome-wide studies of malignancies of the central nervous system (CNS) have revolutionized our understanding of the biology of these tumors. This newly gained knowledge provides a wealth of opportunity for biomarker-driven clinical research. To date, however, only few of the available molecular markers truly influence clinical decision-making and treatment. The most widely validated markers in neuro-oncology presently are: (i) MGMT promoter methylation as a prognostic and predictive marker in glioblastoma; (ii) codeletion of 1p and 19q differentiating oligodendrogliomas from astrocytomas; (iii) IDH1/2 mutations; and (iv) select pathway-associated mutations. This article focuses on currently impactful biomarkers in adult and pediatric brain cancers and it provides a perspective on the direction of research in this field.
Keywords:	Biomarker, BRAF Mutation, Codeletion of 1p/19q, Glioma, Glioblastoma, IDH Mutation, Medulloblastoma, Codeletion, MGMT Promoter Methylation
Source:	Trends in Cancer
ISSN:	2405-8033
Publisher:	Elsevier
Volume:	2
Number:	7
Page Range:	338-349
Date:	July 2016
Additional Information:	Copyright © 2016 Elsevier Inc. All rights reserved.
Official Publication:	https://doi.org/10.1016/j.trecan.2016.06.003
External Fulltext:	View full text on PubMed Central
PubMed:	View item in PubMed

Repository Staff Only: item control page